A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 148-152

  Kaye, S B ^a   Poole, C J ^b   Danska Bidzinska A ^c   Gianni, L ^d   Del Conte, G ^e   Gorbunova, V ^f   Novikova, E ^g   Strauss, A ^h   Moczko, M ^h   McNally, V A ⁱ   Ross, G ⁱ   Vergote, I ^j  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^g V Moscow Reg Sci Res Clin Inst   (Russian Federation)

^h ROCHE DIAGNOSTICS GMBH   (Germany)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Chemotherapy; Human epidermal growth factor receptor; Ovarian cancer; Pertuzumab; Progression free survival; Treatment free interval

Indexed keywords

CARBOPLATIN; GAMMA UROGASTRONE; GEMCITABINE; PACLITAXEL; PERTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPOKALEMIA; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; MULTICENTER STUDY; OVARY TUMOR; PATHOPHYSIOLOGY; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECURRENCE;

EID: 84879188868     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds282     Document Type: Article

References (28)

1. Ferlay J, Autier P, Boniol M et al Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. du Bois A, Lück HJ, Meier W et al A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1330.
3. Ozols RF, Bundy BN, Greer BE et al Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
4. Harries M, Gore M. Overview of epithelial cancer management. Part II Treatment of recurrent disease. Lancet Oncol 2002; 3: 537-545
5. Han L, Kipps E, Kaye SB. Current treatment and clinical trials in ovarian cancer. Expert Opin Invest Drugs 2010; 19: 1-14.
6. Bartlett JM, Langdon SP, Simpson BJ et al The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996; 73: 301-306.
7. Bast RC, Jr, Pusztai L, Kerns BJ et al Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 1998; 17: 313-321.
8. Berchuck A, Kamel A, Whitaker R et al Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
9. Campiglio M, Ali S, Knyazev PG et al. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J Cell Biochem 1999; 73: 522-532.
10. Slamon DJ, Godolphin W, Jones LA et al Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
11. Tanner B, Hasenclever D, Stern K et al ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006; 24: 4317-4323.
12. Holbro T, Beerli RR, Maurer F et al The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003; 100: 8933-8938.
13. Tzahar E, Waterman H, Chen X et al A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-5287.
14. Rodriguez GC, Berchuck A, Whitaker RS et al Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 1991; 164: 745-750.
15. Franklin MC, Carey KD, Vajdos FF et al Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328.
16. Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci 2008; 1130: 280-286.
17. Takai N, Jain A, Kawamata N et al 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005; 104: 2701-2708.
18. Gordon MS, Matei D, Aghajanian C et al Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24: 4324-4332.
19. Makhija S, Amler LC, Glenn D et al Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010; 28: 1215-1223.
20. Hancock MC, Langton BC, Chan T et al A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-4580.
21. Pegram MD, Konecny GE, O'Callaghan C et al Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749.
22. Suter T, Brammer M, Ross G et al. Pooled analysis of cardiac safety in patients treated with pertuzumab. Cancer Res 2009; 69(24 Suppl): Abstract 5088.
23. Vergote I, Rustin GJ, Eisenhauer EA et al Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000; 92: 1534-1535.
24. Engelman JA, J̈nne PA, Mermel C et al ErbB3 mediates phosphoinositide 3- kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005; 102: 3788-3793.
25. Westfall SD, Skinner MK. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 2005; 4: 1764-1771.
26. Parmar MK, Ledermann JA, Colombo N et al Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
27. Pfisterer J, Plante M, Vergote I et al Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
28. Kaye SB, Poole CJ, Bidzinksi M, Gianni L, Gorbunova V, Novikova E, Strauss A, McNally VA Ross G, Vergote I. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed.platinum sensitive ovarian cancer. J Clin Oncol 2008; 26(15S): 5520. (2008 ASCO Annual Meeting Proceedings Post-Meeting Edition).